Covid-19 Vaccine Effectiveness and the Test-Negative Design
Observational studies are emerging as fundamental sources of information about vaccine effectiveness outside the controlled environment of randomized trials, and they are being used to generate evidence of effectiveness against outcomes that are underpowered in trials, such as hospitalization or int...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-10, Vol.385 (15), p.1431-1433 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1433 |
|---|---|
| container_issue | 15 |
| container_start_page | 1431 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Dean, Natalie E Hogan, Joseph W Schnitzer, Mireille E |
| description | Observational studies are emerging as fundamental sources of information about vaccine effectiveness outside the controlled environment of randomized trials, and they are being used to generate evidence of effectiveness against outcomes that are underpowered in trials, such as hospitalization or intensive care unit (ICU) admission, or for narrow subgroups.
1
These studies can monitor the waning of vaccine effectiveness or measure the performance of vaccines against novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants when large randomized, controlled trials are not feasible.
2
Thompson et al.
3
now describe in the
Journal
the application of a retrospective test-negative design to estimate coronavirus . . . |
| doi_str_mv | 10.1056/NEJMe2113151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8451180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2571051927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-bac7e15e51740e29d5da84d5cbcf1ec957fdc652e3add3271accdaed71627d1d3</originalsourceid><addsrcrecordid>eNptkc1LAzEQxYMoWj9unmVBDx5czWySTYMgSK1faL2o15Ams3VLN1s324L_vSmtouJc5jA_Hu_NI2Qf6ClQkZ8N-vePmAEwELBGOiAYSzmn-TrpUJp1Uy4V2yLbIYxpHOBqk2wxzlUOSnTIea-ely4Flbwaa0uPSb8o0LblHD2GkBjvkvYNk2cMbTrAkVlckisM5cjvko3CTALurfYOebnuP_du04enm7ve5UNqOYc2HRorEQQKkJxippxwpsudsENbAFolZOFsLjJkxjmWSYhGnEEnIc-kA8d2yMVSdzobVugs-rYxEz1tyso0H7o2pf598eWbHtVz3eUCoEujwPFKoKnfZzGJrspgcTIxHutZ0JmQ8ZWgMhnRwz_ouJ41PsZbUEqCyhmL1MmSsk0dQoPFtxmgetGK_tlKxA9-BviGv2qIwNESqKqgPY6r_3U-Ac2Sklc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579719633</pqid></control><display><type>article</type><title>Covid-19 Vaccine Effectiveness and the Test-Negative Design</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><source>New England Journal of Medicine Current</source><source>ProQuest Central UK/Ireland</source><creator>Dean, Natalie E ; Hogan, Joseph W ; Schnitzer, Mireille E</creator><creatorcontrib>Dean, Natalie E ; Hogan, Joseph W ; Schnitzer, Mireille E</creatorcontrib><description>Observational studies are emerging as fundamental sources of information about vaccine effectiveness outside the controlled environment of randomized trials, and they are being used to generate evidence of effectiveness against outcomes that are underpowered in trials, such as hospitalization or intensive care unit (ICU) admission, or for narrow subgroups.
1
These studies can monitor the waning of vaccine effectiveness or measure the performance of vaccines against novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants when large randomized, controlled trials are not feasible.
2
Thompson et al.
3
now describe in the
Journal
the application of a retrospective test-negative design to estimate coronavirus . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe2113151</identifier><identifier>PMID: 34496195</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Bias ; Case-Control Studies ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 Vaccines ; Effectiveness ; Hospitalization ; Humans ; Immunization ; Infectious Disease ; Medical Statistics ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine efficacy ; Vaccines</subject><ispartof>The New England journal of medicine, 2021-10, Vol.385 (15), p.1431-1433</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-bac7e15e51740e29d5da84d5cbcf1ec957fdc652e3add3271accdaed71627d1d3</citedby><cites>FETCH-LOGICAL-c441t-bac7e15e51740e29d5da84d5cbcf1ec957fdc652e3add3271accdaed71627d1d3</cites><orcidid>0000-0001-7959-7361</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe2113151$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2579719633?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34496195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dean, Natalie E</creatorcontrib><creatorcontrib>Hogan, Joseph W</creatorcontrib><creatorcontrib>Schnitzer, Mireille E</creatorcontrib><title>Covid-19 Vaccine Effectiveness and the Test-Negative Design</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Observational studies are emerging as fundamental sources of information about vaccine effectiveness outside the controlled environment of randomized trials, and they are being used to generate evidence of effectiveness against outcomes that are underpowered in trials, such as hospitalization or intensive care unit (ICU) admission, or for narrow subgroups.
1
These studies can monitor the waning of vaccine effectiveness or measure the performance of vaccines against novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants when large randomized, controlled trials are not feasible.
2
Thompson et al.
3
now describe in the
Journal
the application of a retrospective test-negative design to estimate coronavirus . . .</description><subject>Bias</subject><subject>Case-Control Studies</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Effectiveness</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infectious Disease</subject><subject>Medical Statistics</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkc1LAzEQxYMoWj9unmVBDx5czWySTYMgSK1faL2o15Ams3VLN1s324L_vSmtouJc5jA_Hu_NI2Qf6ClQkZ8N-vePmAEwELBGOiAYSzmn-TrpUJp1Uy4V2yLbIYxpHOBqk2wxzlUOSnTIea-ely4Flbwaa0uPSb8o0LblHD2GkBjvkvYNk2cMbTrAkVlckisM5cjvko3CTALurfYOebnuP_du04enm7ve5UNqOYc2HRorEQQKkJxippxwpsudsENbAFolZOFsLjJkxjmWSYhGnEEnIc-kA8d2yMVSdzobVugs-rYxEz1tyso0H7o2pf598eWbHtVz3eUCoEujwPFKoKnfZzGJrspgcTIxHutZ0JmQ8ZWgMhnRwz_ouJ41PsZbUEqCyhmL1MmSsk0dQoPFtxmgetGK_tlKxA9-BviGv2qIwNESqKqgPY6r_3U-Ac2Sklc</recordid><startdate>20211007</startdate><enddate>20211007</enddate><creator>Dean, Natalie E</creator><creator>Hogan, Joseph W</creator><creator>Schnitzer, Mireille E</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7959-7361</orcidid></search><sort><creationdate>20211007</creationdate><title>Covid-19 Vaccine Effectiveness and the Test-Negative Design</title><author>Dean, Natalie E ; Hogan, Joseph W ; Schnitzer, Mireille E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-bac7e15e51740e29d5da84d5cbcf1ec957fdc652e3add3271accdaed71627d1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bias</topic><topic>Case-Control Studies</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Effectiveness</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infectious Disease</topic><topic>Medical Statistics</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dean, Natalie E</creatorcontrib><creatorcontrib>Hogan, Joseph W</creatorcontrib><creatorcontrib>Schnitzer, Mireille E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dean, Natalie E</au><au>Hogan, Joseph W</au><au>Schnitzer, Mireille E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Covid-19 Vaccine Effectiveness and the Test-Negative Design</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-10-07</date><risdate>2021</risdate><volume>385</volume><issue>15</issue><spage>1431</spage><epage>1433</epage><pages>1431-1433</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Observational studies are emerging as fundamental sources of information about vaccine effectiveness outside the controlled environment of randomized trials, and they are being used to generate evidence of effectiveness against outcomes that are underpowered in trials, such as hospitalization or intensive care unit (ICU) admission, or for narrow subgroups.
1
These studies can monitor the waning of vaccine effectiveness or measure the performance of vaccines against novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants when large randomized, controlled trials are not feasible.
2
Thompson et al.
3
now describe in the
Journal
the application of a retrospective test-negative design to estimate coronavirus . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34496195</pmid><doi>10.1056/NEJMe2113151</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7959-7361</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-10, Vol.385 (15), p.1431-1433 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8451180 |
| source | MEDLINE; Free E-Journal (出版社公開部分のみ）; New England Journal of Medicine Current; ProQuest Central UK/Ireland |
| subjects | Bias Case-Control Studies Coronavirus Coronaviruses COVID-19 COVID-19 Vaccines Effectiveness Hospitalization Humans Immunization Infectious Disease Medical Statistics SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines |
| title | Covid-19 Vaccine Effectiveness and the Test-Negative Design |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A59%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Covid-19%20Vaccine%20Effectiveness%20and%20the%20Test-Negative%20Design&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dean,%20Natalie%20E&rft.date=2021-10-07&rft.volume=385&rft.issue=15&rft.spage=1431&rft.epage=1433&rft.pages=1431-1433&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe2113151&rft_dat=%3Cproquest_pubme%3E2571051927%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579719633&rft_id=info:pmid/34496195&rfr_iscdi=true |